dgat2

PF-06424439 methanesulfonate, an orally administered, potent, and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM, demonstrates slow reversibility and time-dependent inhibition. It operates in a noncompetitive manner relative to the acyl-CoA substrate, marking its efficacy in targeting DGAT2.

JNJ-DGAT2-B is a selective inhibitor of Diacylglycerol acyltransferase 2.

DGAT2-IN-3 (compound 9) is an inhibitor of DGAT2 with an IC50 value of 0.4 nM. It is utilized in research related to fatty liver disease, diabetes, and cardiovascular diseases.

JNJ-DGAT2-A, a specific inhibitor of DGAT2(IC50 = 0.14 μM), can be used in studies about the synthesis of triglycerides.

H2-005 is a selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2).

PF-07202954, a weakly basic diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor, exhibits an inhibition concentration half-maximum (IC50) of 10 nM against human DGAT2 and effectively reduces liver triglyceride content in a rat model fed on a Western diet [1].

Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. Ervogastat reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).

Diacylglycerolacyltransferaseinhibitor-2 (Example 8) acts as an inhibitor for diacylglycerol acyltransferase 2 (DGAT2), exhibiting an IC50 value of 3.7 nM.

PF-06424439 is an oral and selective inhibitor of imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) (IC50 of 14 nM).

H2-003 is a selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2).